secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001437749-24-036752
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree receives Nasdaq delisting notices for board independence and bid price deficiencies
--------------------------------------------------------------------------------

- CEO appointment Jed Latkin (former independent director) on Dec 1, 2024 caused loss of majority independent board and audit committee shortfall.
- Non-compliance with Nasdaq Rules 5605(b)(1) and 5605(c)(2)(A); cure period until Dec 1, 2025 or next annual meeting.
- Bid price deficiency: closing bid below $1.00 for 30 consecutive days; ineligible for 180-day grace due to two reverse stock splits (cumulative >250:1) in prior 2 years.
- Company intends to request a hearing before Nasdaq Hearings Panel to stay delisting; no assurance of regaining compliance.
- Common stock continues trading on Nasdaq under symbol WINT; delisting risk remains if compliance not restored.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774924036752/0001437749-24-036752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774924036752/wint20241205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer